Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Status:
Recruiting
Trial end date:
2022-10-25
Target enrollment:
Participant gender:
Summary
This is a phase II open-label study investigating the efficacy, safety and
pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with
recurrent glioblastoma(GBM). All patients will have been previously treated with the
standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and
in some cases treatment for recurrent disease. Patients with unequivocal recurrence (first or
greater) established by MRI and meeting inclusion and exclusion criteria, will be eligible
for OKN-007 treatment on this protocol.